359 related articles for article (PubMed ID: 33545758)
1. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
[TBL] [Abstract][Full Text] [Related]
2. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
4. [Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy
in Elderly Patients with Advanced NSCLC].
Mao Y; Sheng S; Wang A; Zhai J; Ge X; Lu D; Wang J
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):367-375. PubMed ID: 38880924
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
[TBL] [Abstract][Full Text] [Related]
9. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; Pizzutilo EG; Bartoli G; Baldessari C; Novello S; Bria E; Cortinovis DL; Rossi G; Rossi A; Banna GL; Camisa R; Di Maio M; Tiseo M
Eur J Cancer; 2020 May; 130():155-167. PubMed ID: 32220780
[TBL] [Abstract][Full Text] [Related]
10. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
Gridelli C; Peters S; Mok T; Forde PM; Reck M; Attili I; de Marinis F
ESMO Open; 2022 Feb; 7(1):100355. PubMed ID: 34922299
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
12. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
13. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Kano H; Ichihara E; Harada D; Inoue K; Kayatani H; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Ninomiya K; Hotta K; Maeda Y; Kiura K
Cancer Sci; 2020 Oct; 111(10):3739-3746. PubMed ID: 32726470
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T; Saruwatari K; Ikeda T; Moriyama E; Kashiwabara K; Shingu N; Iyonaga K; Inaba M; Ajishi Y; Honda C; Hirosako S; Maruyama H; Kakiuchi Y; Eida H; Tomita Y; Saeki S; Ichiyasu H; Sakagami T
Int J Clin Oncol; 2021 Jan; 26(1):78-86. PubMed ID: 32965577
[TBL] [Abstract][Full Text] [Related]
20. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
